ANN ARBOR, Mich., May 3, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that positive interim results from the company’s U.S. Phase 2b trial designated RESTORE-CLI has been accepted for presentation at this year’s Vascular Annual Meeting® of the Society for Vascular Surgery. These promising interim results will be presented by Richard J. Powell, M.D., section chief of vascular surgery at the Dartmouth-Hitchcock Medical Center in Lebanon, NH and a principal investigator of the study.
